USD
+$0.00
(+0.00%
)At Close (As of Sep 9, 2025)
$3.45B
Market Cap
-
P/E Ratio
-2
EPS
$44.34
52 Week High
$19.75
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $251M |
Total Revenue | $399M |
Cost Of Revenue | $148M |
Costof Goods And Services Sold | $148M |
Operating Income | -$282M |
Selling General And Administrative | $299M |
Research And Development | $235M |
Operating Expenses | $533M |
Investment Income Net | - |
Net Interest Income | $35M |
Interest Income | $37M |
Interest Expense | $2.3M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $20M |
Income Before Tax | -$257M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$257M |
Comprehensive Income Net Of Tax | - |
Ebit | -$255M |
Ebitda | -$235M |
Net Income | -$257M |
Field | Value (USD) |
---|---|
Total Assets | $1.2B |
Total Current Assets | $1.1B |
Cash And Cash Equivalents At Carrying Value | $450M |
Cash And Short Term Investments | $450M |
Inventory | $40M |
Current Net Receivables | $89M |
Total Non Current Assets | $135M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $59M |
Intangible Assets Excluding Goodwill | $59M |
Goodwill | - |
Investments | - |
Long Term Investments | $3.1M |
Short Term Investments | $330M |
Other Current Assets | $142M |
Other Non Current Assets | - |
Total Liabilities | $345M |
Total Current Liabilities | $299M |
Current Accounts Payable | $101M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $140M |
Total Non Current Liabilities | $45M |
Capital Lease Obligations | $22M |
Long Term Debt | - |
Current Long Term Debt | $132M |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $153M |
Other Current Liabilities | $54M |
Other Non Current Liabilities | $325K |
Total Shareholder Equity | $841M |
Treasury Stock | - |
Retained Earnings | -$2.5B |
Common Stock | $7K |
Common Stock Shares Outstanding | $99M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$215M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $12M |
Capital Expenditures | $62M |
Change In Receivables | - |
Change In Inventory | $3.9M |
Profit Loss | - |
Cashflow From Investment | -$375M |
Cashflow From Financing | $350M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$257M |
Field | Value (USD) |
---|---|
Gross Profit | $251M |
Total Revenue | $399M |
Cost Of Revenue | $148M |
Costof Goods And Services Sold | $148M |
Operating Income | -$282M |
Selling General And Administrative | $299M |
Research And Development | $235M |
Operating Expenses | $533M |
Investment Income Net | - |
Net Interest Income | $35M |
Interest Income | $37M |
Interest Expense | $2.3M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $20M |
Income Before Tax | -$257M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$257M |
Comprehensive Income Net Of Tax | - |
Ebit | -$255M |
Ebitda | -$235M |
Net Income | -$257M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Zai Lab Limited, a biopharmaceutical company, discovers, licenses, develops and markets therapies to treat cancer, autoimmune and infectious diseases in China. The company is headquartered in Shanghai, China.